Category «vaccines»

Sinovac COVID-19 vaccine, CoronaVac,

Sinovac COVID-19 vaccine, CoronaVac, PiCoVacc CoronaVac, also known as the Sinovac COVID-19 vaccine,[1] is an inactivated virus COVID-19 vaccine developed by the Chinese company Sinovac Biotech.[2] It has been in Phase III clinical trials in Brazil,[3] Chile,[4] Indonesia,[5] the Philippines,[6] and Turkey.[7] It relies on traditional technology similar to BBIBP-CorV and BBV152, other inactivated-virus COVID-19 vaccines in Phase III trials.[8] CoronaVac does not need to be frozen, and both the vaccine and raw material for …

Sputnik V, Gam-COVID-Vac, Gamaleya

Sputnik V Gam-COVID-Vac Gamaleya SARS-CoV-2 Gam-COVID-Vac Lyo Gam-COVID-Vac was created by Gamaleya Research Institute of Epidemiology and MIcrobiology in Russia. The vaccine candidate is a heterologous COVID-19 vaccine containing two components, recombinant adenovirus type 26 (rAd26) vector and recombinant adenovirus type 5 (rAd5) vector which both carry the SARS-CoV-2 spike glycoprotein. The vaccine is …

NOVAWAX, NVX-CoV2373,

NOVAWAX NVX-CoV2373 SARS-CoV-2 rS Nanoparticle Vaccine MCDC OTA agreement number W15QKN-16-9-1002 Novavax COVID-19 vaccine, Coronavirus disease 19 infection SARS-CoV-2 rS, TAK 019 Novavax, Inc. is an American vaccine development company headquartered in Gaithersburg, Maryland, with additional facilities in Rockville, Maryland and Uppsala, Sweden. As of 2020, it had an ongoing Phase III clinical trial in older adults for its candidate vaccine for seasonal influenza, NanoFlu and a candidate vaccine (NVX-CoV2373) …

BBIBP-CorV, Sinopharm COVID-19 vaccine

BBIBP-CorV, Sinopharm COVID-19 vaccine CAS Number 2503126-65-4 Inactivated novel coronavirus (2019-CoV) vaccine (Vero cells) Purified inactivated SARS-CoV-2 Vaccine ref Lancet Infectious Diseases (2021), 21(1), 39-51. BBIBP-CorV, also known as the Sinopharm COVID-19 vaccine,[1] is one of two inactivated virus COVID-19 vaccines developed by Sinopharm. In late December 2020, it was in Phase III trials in Argentina, Bahrain, Egypt, Morocco, Pakistan, Peru, and the United Arab Emirates (UAE) with over 60,000 participants.[2] On December 9, the …

First FDA-approved vaccine Dengvaxia for the prevention of dengue disease in endemic regions

First FDA-approved vaccine for the prevention of dengue disease in endemic regions May 01, 2019 The U.S. Food and Drug Administration announced today the approval of Dengvaxia, the first vaccine approved for the prevention of dengue disease caused by all dengue virus serotypes (1, 2, 3 and 4) in people ages 9 through 16 who …

Zydus Cadila to launch India’s 1st Tetravalent Inactivated Influenza vaccine – VaxiFlu – 4

Zydus Cadila to launch India’s 1st Tetravalent Inactivated Influenza vaccine – VaxiFlu – 4 Ahmedabad, February 24, 2017 Zydus Cadila, a research-driven, global healthcare provider has received approvals from the Drug Controller General of India (DCGI), Central Drugs Standard Control Organization (CDSCO) and the Central Drug Laboratory (CDL) to market the Tetravalent Inactivated Influenza vaccine …